<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two women with recurrent <z:hpo ids='HP_0003002'>breast cancer</z:hpo> presenting with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo>) during chemotherapy were reported </plain></SENT>
<SENT sid="1" pm="."><plain>At diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, white blood cell count, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and platelet count were 3,300/mm3, 4600/mm3, 5.5 g/dl, 6.3 g/dl, 1.1 x 10(4)/mm3 and 6.8 x 10(4)/mm3, respectively, in case 1 and 2 </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow taps showed hypercellular marrows with dysplastic changes of erythrocytes, granulocytes and megakaryocytes in both cases </plain></SENT>
<SENT sid="3" pm="."><plain>Before the occurrence of the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, both patients received various cytotoxic agents (<z:chebi fb="0" ids="27504">mitomycin C</z:chebi>: 77 mg, 108 mg; <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>: 34,400 mg, 40,000 mg; <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>: 340 mg, 460 mg; <z:chebi fb="0" ids="44185">methotrexate</z:chebi>: 410 mg, 700 mg; and <z:chebi fb="0" ids="28445">vincristine</z:chebi>: 9.5 mg, 14 mg, in case 1 and 2, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>One patient died 2 months after the <z:hpo ids='HP_0003674'>onset</z:hpo> of the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and the other died 3 months after due to progression of metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Risk-benefits analysis of chemotherapy, especially adjuvant chemotherapy, should be performed in cases of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>